Express2 Revises Boston Scientific’s U.S. Stent Sales; Japan Nir Sales Sag
This article was originally published in The Gray Sheet
Executive Summary
Rapid uptake of the Express2 stent confirms Boston Scientific's expectation that the internally developed platform will revitalize its languishing stent business as the company awaits the introduction of a drug-eluting counterpart
You may also be interested in...
Boston Scientific Cuts Medinol Ties With Express2 Stent Approval In U.S.
Boston Scientific will no longer depend on Israeli firm Medinol for its coronary stents in the U.S. after gaining FDA approval of its Express2 stent Sept. 12
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.